JNJ

Johnson & Johnson (NYSE: JNJ) Exec Says Co Expects To File For Regulatory Approval For Lung Cancer Therapy In 2025.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our target price at $162, 14.8x our 2024 EPS estimate, below JNJ’s five-year historical forward P/E average. We lift our 2023 EPS estimate by $0.14 to $10.18 and keep our 2024 EPS estimate at $10.94. Q3 EPS of $2.66 vs. $2.23 (+19.3% Y/ Y) was $0.16 above our estimate and $0.14 above consensus. Q3 revenues of $21.4B outperformed expectations, up 6.8% Y/Y, $302M above consensus, due to better-than-anticipated sales performance in the U.S. (+11.1% Y/Y), offsetting slow growth internationally (+1.6% Y/Y). Following the separation with Kenvue, JNJ reports two main businesses: Pharma, going forward referred as Innovative Medicine (65% of total, +5.1% Y/Y), and Medtech (35% of total, +10% Y/Y). Robust growth in Medtech was driven by Interventional Solutions (+47% Y/Y), which also includes contributions

Johnson & Johnson (NYSE: JNJ) Full-Year 2023 Guidance Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.   ($ in Billions, except EPS) October 2023 August 2023 Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point 7.2% – 7.7% / 7.5% 6.2% – 7.2% / 6.7% Operational Sales2,5/ Mid-point Change vs. Prior Year / Mid-point $84.4B – $84.8B / $84.6B 8.5% – 9.0% / 8.7% $83.6B – $84.4B / $84.0B 7.5% – 8.5% / 8.0% Estimated Reported Sales3,5/ Mid-point Change vs. Prior Year / Mid-point $83.6B – $84.0B / $83.8B 7.5% – 8.0% /

Johnson & Johnson (NYSE: JNJ) Q3 Adj. EPS $2.66 Vs. $2.23 a Year Ago, Beats the FactSet Consensus $2.52。

Barclays analyst Matt Miksic maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price target from $158 to $162.

Johnson & Johnson (NYSE:JNJ) reported fiscal Q2 adjusted earnings  of $2.80 per diluted share, up from $2.59 a year earlier. Analysts polled by Capital IQ expected $2.62. Sales for the quarter ended July 2 were $25.53 billion, up from $24.02 billion a year earlier. Analysts surveyed by Capital IQ expected $24.67 billion. Johnson & Johnson (NYSE:JNJ) said it now expects fiscal 2023 adjusted earnings of $10.70 to $10.80 per diluted share, compared with its prior guidance of $10.60 to $10.70 per diluted share. Analysts polled by Capital IQ are looking for $10.65. Sales for the fiscal year are now projected to be $98.8 billion to $99.8 billion, compared with $97.9 billion to $98.9 billion previously, the company said. Analysts surveyed by Capital IQ are expecting $98.91 billion.